After a tumultuous beginning to the year, Adverum Biotechnologies (NasdaqCM:ADVM) has received a much-needed morale booster with a revised one-year price target of 4.28 per share, marking a substantial 10.53% increase from the earlier estimate of 3.88 on January 16, 2024.
The revised price target serves as an average derived from various analyst assessments. Recent targets span from a modest 3.03 to a bullish 6.30 per share. Notably, the average price target signifies a whopping 114.20% surge from the most recent closing price of 2.00 per share.
Fund Sentiment:
The landscape of institutional involvement in Adverum Biotechnologies appears to be shifting, with a total of 96 funds or institutions disclosing their positions. This represents a minor decline of 2 owners, accounting for a 2.04% decrease in the last quarter.
On average, the portfolio weight dedicated to ADVM across all funds now stands at 0.08%, demonstrating a significant 56.34% drop. Total institutional shareholding has receded by 0.47% over the last three months, amounting to 64,567K shares.
Shareholders Actions:
Amidst this changing tide, notable investors like Commodore Capital, FBIOX – Biotechnology Portfolio, VR Adviser, Versant Venture Management, and BML Capital Management have made substantial moves in their ADVM positions.
For instance, Commodore Capital has maintained its stake at 10,000K shares, constituting 9.90% ownership. In contrast, FBIOX reported a reduction in its allocation by 17.56%, while VR Adviser downsized its portfolio by 27.70%.
Conversely, BML Capital Management increased its holdings by 14.04%, albeit decreasing its overall investment in ADVM by 51.84% in the last quarter.
Adverum Biotechnologies in Brief
Stepping back, Adverum Biotechnologies is a pioneering player in the gene therapy arena, with a focus on addressing unmet needs in severe ocular and rare ailments. Central to its innovation is ADVM-022, a groundbreaking gene therapy candidate administered through a single, intravitreal injection.
In this era of rapid technological advancement, Adverum is at the forefront of clinical development, particularly in the treatment of patients grappling with wet age-related macular degeneration and diabetic macular edema.
For those navigating the complex world of investing and seeking comprehensive research tools, Fintel stands out as an invaluable resource catering to individual investors, traders, financial advisors, and small hedge funds.
Rooted in expansive data coverage spanning the globe, Fintel offers a wealth of information ranging from fundamentals, analyst reports, and ownership insights to fund sentiment, insider trading, and options flow, among other critical datasets. Enhanced by cutting-edge quantitative models, the platform’s exclusive stock picks aim to optimize investment returns through rigorously backtested strategies.
Want to delve deeper into this intriguing realm? Click to Learn More and uncover a wealth of opportunities waiting to be explored.
This insider peek originally debuted on Fintel, illuminating key insights for the discerning investor.
Remember, the thoughts and opinions articulated herein represent the author’s perspective and do not necessarily mirror those of Nasdaq, Inc.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
